MDXG
BuyPremium GrowerAI neutralMiMedx Group, Inc. · Healthcare · United States · $696M cap · $5.1M/day traded
$4.69 -2.9% · close 13 Oct · scored 14 Oct
Premium Grower: Strong business with the market behind it, priced at a premium.
Report expected 28 Oct: the next-year EPS estimate has risen 39.5% over the last 13 weeks.
As of 14 Oct 2026, MoatMap's StockRank for MiMedx Group, Inc. (MDXG) is 74/100, ranked against 24,000+ stocks in 35 markets (Quality 70, Value 39, Momentum 60, each scored against its sector).
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
MiMedx makes placental tissue products for wound care and surgery, is growing its surgical business, and recently won a favourable federal court ruling on the regulatory classification of AXIOFILL. Forward EPS estimates rose 15.4% in four weeks and it is buying back shares. Growth is real, but revenue depends heavily on Medicare reimbursement rules for skin substitutes, which are being reset.
ABOUT MIMEDX GROUP, INC.
Read
MiMedx Group, Inc. is a biopharmaceutical company specializing in the development and commercialization of regenerative and therapeutic biologics derived from human placental tissue. Its proprietary allograft products, including AmnioFix and EpiFix, hold a leading position in advanced wound care and surgical recovery markets, backed by extensive clinical evidence and patent-protected processing technologies. MiMedx is a pioneer in regenerative medicine, offering innovative solutions for complex medical conditions.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 267.8M | 321.5M | 348.9M | 418.6M | 16.1% | 355.2M | 269.8M | 328.6M | -11.4% |
| EPS | -0.33 | 0.40 | 0.29 | 0.33 | -9.2% | 0.04 | — | — | — |
| Shares | 113.7M | 146.2M | 146.9M | 148.1M | +30.2% | 145.9M | — | — | — |
| Debt | 48.6M | 49.1M | 18.8M | 18.0M | -28.2% | 17.2M | — | — | — |
| Equity | -18.0M | 142.7M | 193.1M | 256.5M | 34.1% | — | — | — | — |
| Op CF | -17.9M | 26.8M | 66.2M | 74.0M | 66.2% | 46.1M | — | — | — |
| Inv CF | -2.7M | -2.2M | -9.6M | -6.9M | — | — | — | — | — |
| Fin CF | -0.6M | -8.6M | -34.2M | -5.4M | — | — | — | — | — |
59% above its 52-week low and back above a rising 50-day average.
Calmer than 53% of stocks we rank over the past year (40% a year).
How this is worked out
StockRank judges the business. The price check reads only the chart: it is the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn like this one cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of MDXG are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| MDXG | MiMedx Group, Inc.(you) | $696M | 74 | Buy |
| ABUS | Arbutus Biopharma Corporation | $961M | 81 | Strong Buy |
| AGEN | Agenus Inc. | $379M | 70 | Buy |
| ZVRA | Zevra Therapeutics, Inc. | $672M | 92 | Strong Buy |
| ADMA | ADMA Biologics, Inc. | $2.2B | 73 | Buy |
| ORMP | Oramed Pharmaceuticals Inc. | $196M | 75 | Buy |
| CRMD | CorMedix Inc. | $599M | 98 | Strong Buy |
| MGTX | MeiraGTx Holdings plc | $1.1B | 57 | Hold |
| RIGL | Rigel Pharmaceuticals, Inc. | $899M | 98 | Strong Buy |
| OABI | OmniAb, Inc. | $696M | 44 | Hold |
Peer medians: ROE -26.1% · P/E 28.5x · Gross margin 64.2%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.